Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.25 | 16.00 | 16.50 | 16.25 | 16.25 | 16.25 | 307 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0125 | -13.00 | 36.74M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 20/11/2024 18:58 | ANd im going to sue Croda because i own 2 shares, and they are withholding market sensitive ummm headlines | putinaire | |
| 20/11/2024 18:51 | Dont ever say they dont give you anything | putinaire | |
| 20/11/2024 18:51 | Well that was a great day - more confetti distributed to the fans | putinaire | |
| 20/11/2024 18:10 | Uncle Tom thinking of switching from OPTI? Must be the magic of the cream? | dudishes | |
| 20/11/2024 16:02 | Don't miss another bus Joe. | the technical trader | |
| 20/11/2024 15:45 | ‘ all details about formulation, functionality… So what am I potentially investing in then ? Umm dunno, just some cream I suppose. Yeah but what does it do? Dunno, functionality is ‘confidential& Oh ffs Surely they’re not going to be giving up national secrets by saying what the functionality of the cream is. Not asking for the secret formula. It might even help a customer who wants to buy some experimental sludge? | kreature | |
| 20/11/2024 12:18 | Back to the best of the day 16p +0.375p | master rsi | |
| 20/11/2024 09:04 | New Cavendish note out today Target Price 56.0p Investment thesis. SkinBioTherapeutics is well positioned within the nascent skin biome market opportunity. The company is progressing the development of the AxisBiotix pillar to enhance the value of this technology to prospective multinational partners, while the commercial agreement with Croda is progressing positively, such that first revenues are expected by the end of 2024. Following the recent acquisitions, SkinBioTherapeutics is also delivering on its previously stated M&A strategy. | radhaz | |
| 20/11/2024 08:57 | It was agood start to the day, with just now the second move up though with a large spread 15.50 v 16.50p +0.375p | master rsi | |
| 19/11/2024 22:01 | Hello, I’d like to buy some cream please… What does this one do? ‘ all details about formulation, functionality… | kreature |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
